Brean Murray Raises PT on Inhibitex to $26

Symbols: BMY, INHX
Share

Brean Murray Carret & Company has raised the price target on Inhibitex (NASDAQ: INHX) from $19 to $26 after the company announced its plans to have all outstanding shares acquired by Bristol-Myers Squibb (NYSE: BMY) for $26/share. Buy rating is maintained on INHX.


 
 
< Previous
Philippines Vehicle Sales Drop 4% In 2011
Next >
From Earlier: Sequenom Sees 2011 Revenue Growth of 23%
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust